Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndromes (MDS): early-phase trial registry
7 of 11 indexed Myelodysplastic Syndromes (MDS) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 7 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Myelodysplastic Syndromes (MDS): 11 US clinical trials tracked, 7 recruiting.
Myelodysplastic Syndromes (MDS) is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndromes-mds
OPEN 7 | RECR 64% | LATE 2 | EARLY 7 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Melanoma (64% recruiting · 22 trials)
Myelodysplastic Syndromes (MDS) lists 7 open slots (64% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndromes (MDS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndromes (MDS) is recruiting above its size-band peers.
7 of 11 indexed trials (63.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myelodysplastic Syndromes (MDS) research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Myelodysplastic Syndromes (MDS) trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.
-
Myelodysplastic Syndromes (MDS) research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
NCT04064060
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Beijing InnoCare Pharma Tech Co.
NCT06656494
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
University of Nebraska
NCT04898790
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05092451
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT05884333
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Institut de Recherches Internationales Servier
NCT06465953
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06398457
A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
Bristol-Myers Squibb
NCT06971185
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
AbbVie
NCT02942290
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT03849651
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
Memorial Sloan Kettering Cancer Center
NCT04872595
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndromes (MDS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndromes (MDS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndromes (MDS) page
11 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Myelodysplastic Syndromes (MDS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Myelodysplastic Syndromes (MDS) trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndromes (MDS) condition card totals 11 registered trials; most-linked intervention Azacitidine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.